| URL | https://www.biopharma-reporter.com/Article/2021/11 |
| Source | BioPharma |
| Date Published | 11/17/2021 |
| Author Name | Ben Hargreaves |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | GeminiBio |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Capital investment ($): | 18.5 |
| City reshored to: | Sacremento |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | process liquids |
| What domestic positive factors made reshoring more attractive? | Lead time/Time to market, Manufacturing/engineering joint innovation (R&D), Raw Materials Cost, U.S. price of natural gas/chemicals/electricity |